469. Outcomes of COVID-19 among hospitalized patients under Rituximab: the experience of a Portuguese hospital

BACKGROUND: Rituximab (RTX) is a monoclonal antibody commonly used for various hematological and autoimmune disorders. B-cell–depleting therapies also blunt humoral responses to SARS-CoV-2 vaccines. Whether this carries an increased risk of hospitalization or death from COVID-19 is unclear. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonçalves, Maria João M S, Pena, Eduarda, Duarte, Frederico, Oliveira, Susana, Batista, Clara, Guimarães, Mário, Abreu, Ricardo Correia, Neves, Isabel, Jordão, Sofia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677196/
http://dx.doi.org/10.1093/ofid/ofad500.539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677196/
http://dx.doi.org/10.1093/ofid/ofad500.539

Ejemplares similares